Investigating ways to overcome drug resistance in acute myeloid leukemia treatment
Targeting AMP Synthesis to Overcome Resistance to BH3 Mimetics in Acute Myeloid Leukemia
This study is looking at how older patients with acute myeloid leukemia (AML) can get better treatment by figuring out why some of them stop responding to a drug called venetoclax, and they hope to find new ways to make the treatment work better for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11132538 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for older patients with acute myeloid leukemia (AML) by understanding how resistance to a specific drug, venetoclax, develops over time. The team will explore the molecular mechanisms behind this resistance, particularly the role of an enzyme called ADSS2 in AMP synthesis. By using advanced techniques like CRISPR/Cas9 and patient-derived models, they aim to identify new therapeutic strategies that could enhance the effectiveness of existing treatments. The ultimate goal is to develop a combination therapy that can better target resistant leukemia cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults aged 60 years and above who have been diagnosed with acute myeloid leukemia.
Not a fit: Patients with acute myeloid leukemia who are younger than 60 years or those who do not have resistance to venetoclax may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for older patients with acute myeloid leukemia, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in targeting drug resistance in leukemia, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Li, Ling — Beckman Research Institute/city of Hope
- Study coordinator: Li, Ling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.